It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Learn which blue chip coins to buy in 2026 and why they stand out in terms of reliability, liquidity, and long-term potential.
25,977 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As mortgage costs rise in 2026, the classic Ramsey guidance on housing is keeping many middle-class families from buy...
Investors eye the Q4 2025 earnings transcript from Up Fintech (TIGR) to gauge growth, margins, and execution. This gu...
A new ETF design keeps protection in place month after month, preventing panic selling during dips by resetting hedge...
A new consumer-ready humanoid named Neo hits preorder with a $20,000 price tag, promising to handle simple chores at ...
Treasury's crypto policy lead is pushing for CLARITY Act passage by summer 2026 and signaling a cautious, deliberatel...
A new government estimate links weekly economic losses from the Israel-Hamas/Iran front to alert levels, while Bitcoi...
SpaceX AI projects Bitcoin to climb to $150,000–$250,000 by end-2026, but a key regulatory catch could cap gains. Mar...
Three consumer-facing stocks — Planet Fitness, Brown-Forman, and Campbell’s — moved on earnings, tariffs, and margin ...
AbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
As SuRo Capital releases its Q4 2025 results, investors need a clear playbook. This deep dive breaks down the key met...
Oil sits near $90 per barrel on June 12, 2026, with Brent guiding the market. Traders weigh supply discipline, demand...